dr. saint fleur-lominy on the use of ruxolitinib versus fedratinib in mpns
Published 4 years ago • 303 plays • Length 0:56Download video MP4
Download video MP3
Similar videos
-
1:26
dr. saint fleur-lominy on impact of ruxolitinib on symptom burden in mpns
-
2:15
dr. saint fleur-lominy on emerging agents in mpns
-
1:18
dr. saint fleur-lominy on remaining challenges in myelofibrosis
-
1:00
dr. mesa on the utility of ruxolitinib versus fedratinib in myelofibrosis
-
1:42
dr. mesa on ruxolitinib vs fedratinib in myelofibrosis treatment
-
1:27
dr. kuykendall on choosing ruxolitinib or fedratinib in myelofibrosis
-
0:50
dr. snyder on how ruxolitinib and fedratinib may pave the way to transplant in myelofibrosis
-
3:52
comparison of ruxolitinib vs fedratinib and practical implications
-
1:12
dr. kuykendall on the approval of fedratinib in myelofibrosis
-
1:31
dr. kuykendall on toxicity profiles of ruxolitinib and fedratinib in myelofibrosis
-
1:11
dr. mesa on the utility of fedratinib for patients with myelofibrosis who progress on ruxolitinib
-
0:59
dr. michaelis on fedratinib in myelofibrosis treatment
-
1:12
dr. mesa on the differences between fedratinib and ruxolitinib in myelofibrosis
-
1:24
dr. mesa on current data with ruxolitinib and fedratinib in myelofibrosis
-
1:08
dr. kiladjian on ruxolitinib plus interferon in mpns
-
2:22
dr. scherber discusses ruxolitinib failure in myelofibrosis
-
1:10
dr. bradley on the utility of ruxolitinib in myelofibrosis and polycythemia vera
-
1:16
dr. mesa on the fda approval of fedratinib in myelofibrosis
-
2:07
fedratinib for myelofibrosis